# Ronan J. Kelly

Source: https://onco.cc/people/ronan-kelly/  
OnCo record `ronan-kelly` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease.

## Summary

Ronan Kelly (Baylor Sammons Cancer Center) was principal investigator of CheckMate 577, which showed adjuvant nivolumab doubles disease-free survival in oesophageal and junctional cancer patients with residual disease after chemoradiotherapy and surgery, the first adjuvant immunotherapy approval in a GI cancer. He continues to lead perioperative immunotherapy trials in upper GI cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: esophageal; immunotherapy; adjuvant
- Role: Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas
- Specialisms: Oesophageal cancer; Gastric cancer; Adjuvant immunotherapy; Thoracic oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kelly%20RJ%5BAuthor%5D%20esophageal%20nivolumab

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Charles A. Sammons Cancer Center, Baylor University Medical Center](https://onco.cc/institutions/baylor-sammons-dallas/)
- trials: [CheckMate 577](https://onco.cc/trials/checkmate-577/)
- journals: [Journal of the National Comprehensive Cancer Network](https://onco.cc/journals/jnccn/)

---
JSON: https://onco.cc/api/v1/entities/ronan-kelly.json